Meeting
2023 ASCO Annual Meeting
Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study.
Authors
Yuankai Shi
Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China
Yuankai Shi , Gongyan Chen , Xiang Wang , Yunpeng Liu , Lin Wu , Yanrong Hao , Chunling Liu , Shuyang Zhu , Xiaodong Zhang , Yuping Li , Jiwei Liu , Lejie Cao , Ying Cheng , Hui Zhao , Shucai Zhang , Ai-min Zang , Jiuwei Cui , Jian Feng , Nong Yang , Jie Hu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03787992
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9081)
DOI
10.1200/JCO.2023.41.16_suppl.9081
Abstract #
9081
Poster Bd #
69
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC.
First Author: Pasi A. Janne
Poster
2021 ASCO Annual Meeting
A multicenter, randomized, double-blind study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER).
First Author: Li Zhang
Poster
2018 ASCO Annual Meeting
A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC).
First Author: Hongyun Zhao